Phenazocine: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 32: | Line 32: | ||
{{stub}} | {{stub}} | ||
== Phenazocine == | |||
<gallery> | |||
File:Phenazocine2DCSD.svg|2D chemical structure of Phenazocine | |||
File:Phenazocine_3D_BS.png|3D ball-and-stick model of Phenazocine | |||
</gallery> | |||
Latest revision as of 01:49, 17 February 2025
Phenazocine is a type of narcotic analgesic that was first synthesized in the 1950s. It is part of the bentazocine family of drugs, which also includes pentazocine and nalbuphine. Phenazocine is not currently used in clinical practice due to its high potential for addiction and overdose.
History[edit]
Phenazocine was first synthesized in the 1950s by the pharmaceutical company Winthrop Laboratories. It was initially marketed as a potent analgesic for the treatment of severe pain. However, due to its high potential for addiction and overdose, it was later withdrawn from the market.
Pharmacology[edit]
Phenazocine is a mu-opioid receptor agonist, which means it binds to and activates the mu-opioid receptors in the brain. This results in a decrease in the perception of pain. However, it also produces a number of side effects, including respiratory depression, constipation, and nausea.
Side Effects[edit]
The most common side effects of phenazocine include nausea, vomiting, constipation, and dizziness. It can also cause severe respiratory depression, which can be fatal in high doses. Other side effects include sedation, confusion, and hallucinations.
Addiction and Overdose[edit]
Phenazocine has a high potential for addiction and overdose. It produces a strong sense of euphoria, which can lead to repeated use and eventually addiction. Overdose can result in severe respiratory depression, which can be fatal.
See Also[edit]
References[edit]
<references />


